As­traZeneca cancer drug gets China nod

New Straits Times - - Business -

BEI­JING: As­traZeneca Plc said it had a key lung cancer drug ap­proved in China, open­ing up a new mar­ket for the ther­apy and al­low­ing the United King­dom’s sec­ond­biggest drug­maker to reach thou­sands of new pa­tients. The com­pany had per­mis­sion to start mar­ket­ing the medicine, named Ta­grisso, in China, it said in a state­ment. As in­ci­dence of dis­eases like cancer and di­a­betes rise in China, the coun­try is be­com­ing in­creas­ingly im­por­tant to the global phar­ma­ceu­ti­cal in­dus­try.

Newspapers in English

Newspapers from Malaysia

© PressReader. All rights reserved.